About Neurodegenerative Disease Research, Inc.

Funded research that directly benefitted ALS patients

 

Neurodegenerative Disease Research, Inc. is a not-for-profit organization that was formed with a mission to fund researchers with an emphasis to identify and validate biomarkers for determining drug effectiveness in neurodegenerative diseases and facilitate pathology-based treatments to ALS patients.  NDR supports open access to all findings via peer-reviewed publications.

NDR has funded projects to date include the following:

 

+ Identifying markers for stressed tissue from adipose-derived stem cells

+ Investigating immune checkpoint cell signaling, in vitro analysis of perivascular stem cell repair of cell damage

+ Evaluating cytokine responses of treated peripheral blood mononuclear cells

+ Studies using SOD1 mouse models of ALS

+ Evaluating the components of conditioned media from various sources

+ Development of secretome as an ALS treatment

+ Modification of therapeutic molecules to increase effectiveness and decrease toxicity in ALS patients

+ Use of DNA and RNA analyses that define ALS phenotypes and metabolomic studies including metabolomics and miRNA studies

+ Bringing the novel retro-inverso thymopentin, a neuroinflammatory modulator, into clinical trials